Anti-VEGF Treatment of Corneal Neovascularization
Anti-VEGF Treatment of Corneal Neovascularization
复制标题
DOI：
10.1016/s1542-0124(11)70035-0
复制
发表时间：
2011-10-01
期刊：
影响因子：
6.4
通讯作者：
Jacobs, Deborah S.
中科院分区：
文献类型：
--
作者：
Keating, Anne M.;Jacobs, Deborah S.
血管内皮生长因子（VEGF）是一种血管生成因子，在肿瘤发生和视网膜新生血管（NV）中是一种重要的分泌型细胞因子。目前，有两种抗VEGF剂，哌加他尼和雷珠单抗，被美国食品和药物管理局（FDA）批准用于玻璃体内用于治疗湿性年龄相关性黄斑变性（AMD）。贝伐珠单抗是FDA批准的用于治疗几种癌症的静脉内给药，并且作为玻璃体内注射广泛使用，标签外，以治疗各种视网膜病变。动物研究证实了VEGF在角膜NV中的作用。现在有许多人类病例系列报告使用抗VEGF药物（主要是贝伐单抗）治疗角膜NV。本文综述了迄今为止关于使用抗VEGF药物治疗人类角膜NV的报道，指出目前数据的局限性和进一步研究的必要性。一个临床医生的经验与使用抗VEGF药物治疗活动性角膜NV。
Vascular endothelial growth factor (VEGF) is an angiogenic factor shown to be a critical secreted cytokine in tumorigenesis and retinal neovascularization (NV). Currently, there are two anti-VEGF agents, pegaptanib and ranizumab, approved by the United States Food and Drug Administration (FDA) for intravitreal use in the treatment of wet age-related macular degeneration (AMD). Bevacizumab is FDA-approved for intravenous administration in the treatment of several cancers and is in widespread use, off-label, as an intravitreal injection to treat a variety of retinal pathologies. Animal studies demonstrate the role of VEGF in corneal NV. There are now a number of human case series reporting the use of anti-VEGF agents, primarily bevacizumab, to treat corneal NV. This review summarizes reports to date on the use of anti-VEGF agents in the treatment of corneal NV in humans, noting the limitations of current data and the need for further studies. The experience of one clinician with the use of an anti-VEGF drug in the treatment of active corneal NV is presented.